Literature DB >> 27127759

Precision medicine in myasthenia graves: begin from the data precision.

Hai-Feng Li1, Yu Hong1, Yanchen Xie1, Hong-Jun Hao1, Ren-Cheng Sun1.   

Abstract

Myasthenia gravis (MG) is a prototypic autoimmune disease with overt clinical and immunological heterogeneity. The data of MG is far from individually precise now, partially due to the rarity and heterogeneity of this disease. In this review, we provide the basic insights of MG data precision, including onset age, presenting symptoms, generalization, thymus status, pathogenic autoantibodies, muscle involvement, severity and response to treatment based on references and our previous studies. Subgroups and quantitative traits of MG are discussed in the sense of data precision. The role of disease registries and scientific bases of precise analysis are also discussed to ensure better collection and analysis of MG data.

Entities:  

Keywords:  Myasthenia gravis (MG); common element data (CDE); phenotype; precision medicine

Year:  2016        PMID: 27127759      PMCID: PMC4828738          DOI: 10.21037/atm.2016.02.16

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  88 in total

Review 1.  Standard outcome measures for thymic malignancies.

Authors:  James Huang; Frank C Detterbeck; Zuoheng Wang; Patrick J Loehrer
Journal:  J Thorac Oncol       Date:  2010-12       Impact factor: 15.609

Review 2.  Lifetime course of myasthenia gravis.

Authors:  David Grob; Norman Brunner; Tatsuji Namba; Murali Pagala
Journal:  Muscle Nerve       Date:  2008-02       Impact factor: 3.217

3.  Comparison of IVIg and PLEX in patients with myasthenia gravis.

Authors:  D Barth; M Nabavi Nouri; E Ng; P Nwe; V Bril
Journal:  Neurology       Date:  2011-05-11       Impact factor: 9.910

4.  Linkage analysis of human systemic lupus erythematosus-related traits: a principal component approach.

Authors:  S Rao; J M Olson; K L Moser; C Gray-McGuire; G R Bruner; J Kelly; J B Harley
Journal:  Arthritis Rheum       Date:  2001-12

5.  Patient registries: useful tools for clinical research in myasthenia gravis.

Authors:  Fulvio Baggi; Renato Mantegazza; Carlo Antozzi; Donald Sanders
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

Review 6.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

Review 7.  Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  Michael Benatar; Henry J Kaminski
Journal:  Neurology       Date:  2007-04-25       Impact factor: 9.910

8.  Clinical Features and Diagnostic Usefulness of Antibodies to Clustered Acetylcholine Receptors in the Diagnosis of Seronegative Myasthenia Gravis.

Authors:  Pedro M Rodríguez Cruz; Michal Al-Hajjar; Saif Huda; Leslie Jacobson; Mark Woodhall; Sandeep Jayawant; Camilla Buckley; David Hilton-Jones; David Beeson; Angela Vincent; Maria Isabel Leite; Jacqueline Palace
Journal:  JAMA Neurol       Date:  2015-06       Impact factor: 18.302

9.  Polymorphisms in the glucocorticoid receptor gene and in the glucocorticoid-induced transcript 1 gene are associated with disease activity and response to glucocorticoid bridging therapy in rheumatoid arthritis.

Authors:  R A M Quax; J W Koper; A M Huisman; A Weel; J M W Hazes; S W J Lamberts; R A Feelders
Journal:  Rheumatol Int       Date:  2015-02-28       Impact factor: 2.631

10.  Outcome of beta-interferon treatment in relapsing-remitting multiple sclerosis: a Bayesian analysis.

Authors:  Killian O'Rourke; Cathal Walsh; Michael Hutchinson
Journal:  J Neurol       Date:  2007-08-14       Impact factor: 6.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.